Pricing Strategy of Wegovy and Zepbound Revealed ??!!

1?? ???????? ??????????????:

??This pricing strategy ???????????????????????? ?????? ???????? ?????? ???????? ???? ???????? ???????????????????? ???? ?????? ????????????, making it easier for prescribers and patients to understand and predict costs

??It simplifies pricing by offering all doses of medications within a brand at the same per-prescription list price

??It helps manufacturers streamline the purchasing process, eliminating the need to calculate varying costs for different dosages

Eg. ???????????????was priced at $935.77 per pen in Nov 2023 (Source:?Novo Nordisk) because each pen delivers 4, once-per-week maintenance doses of Ozempic, the list price is $233.94 per week - ???????? ?????????? ???? ?????? ????????, ???????????????????? ???? ?????????????? ?????? ?????????????? ???? ???????????? 0.5 ???? ?????? ????????, 1.0 ???? ?????? ????????, ???? 2.0 ???? ?????? ????????

2????????????????? ??????????????:

??Illustrated by ???????????? having a higher list price compared to Ozempic, premium pricing can be influenced by supply and demand dynamics, historical pricing patterns, and perceived product value

??????????????'s higher price is attributed to its efficacy and market positioning

3?????????????????????? ??????????????????:

?????????????????? ?????? ???????????????? are priced closely to prevent patients or prescribers from exploiting price differences between similar products. This alignment in pricing helps maintain market stability and avoids unnecessary competition based solely on price

4???????????????????????????? ???? ???????????? ????????????????:

??The pricing strategies of these brands not only consider product efficacy but also market stability, market dynamics, and long-term sustainability.

??Price decisions are calculated to avoid unintended consequences in a competitive market ??Besides list prices, it's essential to consider net prices, copays, and copay assistance programs, which influence the actual cost to health plans and patients

???????????????????????????? ??????????????????????: Currently it is difficult to asses how the evolving landscape of GLP-1 agonists will affect the pricing strategy of Novo Nordisk and Eli Lilly.

??However, with access to longer acting (Once-a month dosing) drugs as well as oral molecules in the coming years, coupled with access to compounded forms of these drugs, which are much cheaper, there are many aspects that need to be considered for these two companies to redo their pricing and reimbursement strategies in order to maintain their position in this crowded market.

???????????????????? ???? ???????? ???????? ?????????? ?????????????? & ???????????? ???????????? ?????? ??????-1 ????????????????, ???? ?????????????? ?????? ???????????????? ???????????? -??????-1 ???????????????? ?????????????????? 2.0-?????? ??????????????????????!